High residual gradients after transcatheter aortic valve implantation in raphe-type bicuspid aortic valve stenosis: insights from the AD-HOC registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tartaglia Francesco, Gitto Mauro, Kim Won-Keun, Leone Pier Pasquale, Fabris Tommaso, De Biase Chiara, Costa Giuliano, Montarello Nicholas, Scotti Andrea, Bellamoli Michele, Alfadhel Mesfer, Koren Ofir, Fezzi Simone, Bellini Barbara, Massussi Mauro, Costa Giulia, Fraccaro Chiara, Mazzapicchi Alessandro, Giacomin Enrico, Burzotta Francesco, Zito Andrea, Gorla Riccardo, Angelillis Marco, Hug Karsten, Briguori Carlo, Bettari Luca, Messina Antonio, Galasso Michele, Regazzoli Damiano, Cattaneo Greta, Boiago Mauro, Calamita Gianmaria, Laterra Giulia, Renker Matthias, Garcia Gomez Mario, Ielasi Alfonso, Landes Uri, Rheude Tobias, Bedogni Francesco, Amat Santos Ignacio, Saia Francesco, Bai Lin, Chen Mao, Adamo Marianna, De Carlo Marco, Montorfano Matteo, Makkar Raj R, Mylotte Darren, Blackman Daniel J, Barbanti Marco, Tchetche Didier, Tarantini Giuseppe, Latib Azeem, Maffeo Diego, De Backer Ole, Buono Andrea, Mangieri Antonio
Аннотация
OBJECTIVE: To identify incidence, predictors and outcomes of HRG after TAVI in Sievers type 1 BAV stenosis.
METHODS: Consecutive patients with Sievers type 1 BAV stenosis undergoing TAVI at 24 international centers from 2016 to 2023 were enrolled. HRG were defined as a mean transvalvular gradient ≥ 20 mmHg at 30 days, according to Valve Academic Research Consortium-3 (VARC-3) criteria. The primary endpoint was major adverse cardiovascular events (MACE), defined as a composite of all-cause death, neurologic events or hospitalization for heart failure, assessed at 3 years after TAVI. Secondary endpoints included the single components of the primary outcome. Endpoints were assessed according to the presence of HRG, before and after covariate adjustment for clinically relevant confounders.
RESULTS: A total of 972 patients were enrolled. HRG post-TAVI were found in 35 patients (3.6%). Patients with HRG had a higher preprocedural aortic valve gradient (57.0 [interquartile range: 49.0-69.0] mmHg vs 48.0 [40.0-58.0] mmHg, p < 0.001) and received smaller transcatheter heart valve (THV) (26.0 [23.0-29.0] mm vs 29.0 [26.0-29.0] mm, p < 0.001) when compared to patients with normal residual gradients (NRG). The only independent predictor of HRG was a bioprosthesis size ≤ 23 mm. At 3 years, MACE occurred in 35.0% of HRG patients and 22.3% of NRG patients (adjusted hazard ratio [HR]: 2.41, 95% confidence interval [CI]: 1.15-5.04; p = 0.019). HRG patients had a higher risk of neurologic events as compared to NRG patients (13.3% versus 4.5%, adjusted HR: 4.50, 95% CI: 1.52-13.30, p = 0.007).
CONCLUSIONS: After TAVI in Sievers type 1 BAV stenosis, HRG occurred in around 4% of cases and were associated with an increased risk of MACE and neurologic events.